Literature DB >> 31776289

Promising disease-modifying therapies for Parkinson's disease.

Valina L Dawson1,2,3,4, Ted M Dawson1,2,3,5.   

Abstract

To date, there is no disease-modifying therapy for Parkinson's disease; however, promising new agents have advanced into clinical trials.
Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh：

Year:  2019        PMID： 31776289     DOI： 10.1126/scitranslmed.aba1659

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN： 1946-6234            Impact factor:   17.956


  19 in total

1.  A zebrafish screen reveals Renin-angiotensin system inhibitors as neuroprotective via mitochondrial restoration in dopamine neurons.

Authors:  Gha-Hyun J Kim; Han Mo; Harrison Liu; Zhihao Wu; Steven Chen; Jiashun Zheng; Xiang Zhao; Daryl Nucum; James Shortland; Longping Peng; Mannuel Elepano; Benjamin Tang; Steven Olson; Nick Paras; Hao Li; Adam R Renslo; Michelle R Arkin; Bo Huang; Bingwei Lu; Marina Sirota; Su Guo
Journal:  Elife       Date:  2021-09-22       Impact factor: 8.140

2.  Articulatory undershoot of vowels in isolated REM sleep behavior disorder and early Parkinson's disease.

Authors:  Dominik Skrabal; Jan Rusz; Michal Novotny; Karel Sonka; Evzen Ruzicka; Petr Dusek; Tereza Tykalova
Journal:  NPJ Parkinsons Dis       Date:  2022-10-20

Review 3.  Microglia and astrocyte dysfunction in parkinson's disease.

Authors:  Tae-In Kam; Jared T Hinkle; Ted M Dawson; Valina L Dawson
Journal:  Neurobiol Dis       Date:  2020-07-28       Impact factor: 5.996

Review 4.  Parkinson's Disease Drug Development Since 1999: A Story of Repurposing and Relative Success.

Authors:  Deirdre M Boucherie; Gonçalo S Duarte; Tiago Machado; Patrícia R Faustino; Cristina Sampaio; Olivier Rascol; Joaquim J Ferreira
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568

5.  Speech Biomarkers in Rapid Eye Movement Sleep Behavior Disorder and Parkinson Disease.

Authors:  Jan Rusz; Jan Hlavnička; Michal Novotný; Tereza Tykalová; Amelie Pelletier; Jacques Montplaisir; Jean-Francois Gagnon; Petr Dušek; Andrea Galbiati; Sara Marelli; Paul C Timm; Luke N Teigen; Annette Janzen; Mahboubeh Habibi; Ambra Stefani; Evi Holzknecht; Klaus Seppi; Elisa Evangelista; Anna Laura Rassu; Yves Dauvilliers; Birgit Högl; Wolfgang Oertel; Erik K St Louis; Luigi Ferini-Strambi; Evžen Růžička; Ronald B Postuma; Karel Šonka
Journal:  Ann Neurol       Date:  2021-05-07       Impact factor: 10.422

Review 6.  Epigenetics in Lewy Body Diseases: Impact on Gene Expression, Utility as a Biomarker, and Possibilities for Therapy.

Authors:  Aintzane Urbizu; Katrin Beyer
Journal:  Int J Mol Sci       Date:  2020-07-02       Impact factor: 5.923

Review 7.  Klotho Pathways, Myelination Disorders, Neurodegenerative Diseases, and Epigenetic Drugs.

Authors:  Walter H Moos; Douglas V Faller; Ioannis P Glavas; David N Harpp; Iphigenia Kanara; Anastasios N Mavrakis; Julie Pernokas; Mark Pernokas; Carl A Pinkert; Whitney R Powers; Konstantina Sampani; Kosta Steliou; Demetrios G Vavvas; Robert J Zamboni; Krishna Kodukula; Xiaohong Chen
Journal:  Biores Open Access       Date:  2020-03-31

Review 8.  Parkinson's Disease Modification Through Abl Kinase Inhibition: An Opportunity.

Authors:  Milton H Werner; C Warren Olanow
Journal:  Mov Disord       Date:  2021-11-23       Impact factor: 9.698

Review 9.  Therapeutic Strategies to Reduce the Toxicity of Misfolded Protein Oligomers.

Authors:  Ryan P Kreiser; Aidan K Wright; Natalie R Block; Jared E Hollows; Lam T Nguyen; Kathleen LeForte; Benedetta Mannini; Michele Vendruscolo; Ryan Limbocker
Journal:  Int J Mol Sci       Date:  2020-11-17       Impact factor: 5.923

Review 10.  Autophagy-Lysosomal Pathway as Potential Therapeutic Target in Parkinson's Disease.

Authors:  Srinivasa Reddy Bonam; Christine Tranchant; Sylviane Muller
Journal:  Cells       Date:  2021-12-15       Impact factor: 6.600
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.